Home > Riviste > International Angiology > Fascicoli precedenti > International Angiology 2017 December;36(6) > International Angiology 2017 December;36(6):558-64

ULTIMO FASCICOLO
 

ARTICLE TOOLS

Publication history
Estratti
Per citare questo articolo

INTERNATIONAL ANGIOLOGY

Rivista di Angiologia


Official Journal of the International Union of Angiology, the International Union of Phlebology and the Central European Vascular Forum
Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,37


eTOC

 

ORIGINAL ARTICLE  


International Angiology 2017 December;36(6):558-64

DOI: 10.23736/S0392-9590.17.03805-6

Copyright © 2017 EDIZIONI MINERVA MEDICA

lingua: Inglese

Chronic venous disease treated with sulodexide: a survey among primary care physicians in Mexico

Luis F. FLOTA CERVERA 1, Alberto C. FRATI MUNARI 2 , Ángel E. VELÁZQUEZ HERRERA 3, Annabella CARBAJAL CONTRERAS 4

1 CEDIME Vascular Institute, Mérida, Mexico; 2 Department of Internal Medicine, Médica Sur Hospital, Mexico City, Mexico; 3 Private Practitioner, Guadalajara, Mexico; 4 Private Practitioner, Reynosa, Mexico


PDF  


BACKGROUND: Sulodexide is a glycosaminoglycan approved for the treatment of chronic venous disease (CVD). It has been available in Mexico since 2012. The aim of the study was to understand the clinical experience of primary care physicians in the treatment of CVD with sulodexide.
METHODS: Clinical data collection forms were distributed among general practitioners. Data was collected for up to four follow-up consultations. All signs and symptoms were rated with the Likert Scale at each examination: 0 to 5 (where 0 means none, and 5 very severe). Both the patient’s and the physician’s opinions of the effects of the treatment were recorded.
RESULTS: Data were collected from 1599 patients at different clinical stages of CVD, 52% of which were at advanced stages (C4-C6). A total of 434 cases were followed up with four examinations (median of thirty days between each examination). In these cases, the overall sign and symptom score decreased significantly at each examination (P<0.01). At the fourth examination, 98.9% of the patients felt better or much better than at the first examination, and 99.7% were better or much better in the physician’s opinion (P<0.01). The only adverse effect was nausea, reported in two cases.
CONCLUSIONS: Sulodexide was effective and well tolerated in the treatment of CVD.


KEY WORDS: Vascular diseases - Venous insufficiency - Sulodexide - Pharmaceutical preparations - Primary care physicians

inizio pagina

Publication History

Issue published online: November 23, 2017
Manuscript accepted: June 27, 2017
Manuscript revised: February 27, 2017
Manuscript received: December 21, 2016

Per citare questo articolo

Flota Cervera LF, Frati Munari AC, Velázquez Herrera ÁE, Carbajal Contreras A. Chronic venous disease treated with sulodexide: a survey among primary care physicians in Mexico. Int Angiol 2017;36:558-64. DOI: 10.23736/S0392-9590.17.03805-6

Corresponding author e-mail

afratim@hotmail.com